Diligence memo · auto-generated · as of July 2, 2026
National Resilience, Inc.
National Resilience, Inc. looks over-valued against its niche peers and is dormant on financing cadence.
Businessfiled
National Resilience, Inc. operates in Biotechnology, based in La Jolla. Resilience is a biomanufacturing CDMO improving access to complex medicines, with end-to-end solutions for safe & scalable biologics manufacturing.
Sub-sector tags: climate/cleantech.
Capital & rounds (filed)filed
National Resilience, Inc. has raised $755M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Growth/Late (a round over $400M).
Largest single filing: $755M on 2020-10-23.
Most recent recorded round closed around 2020-10-23.
Valuation (modeled)modeled
Provath models National Resilience, Inc. at approximately $29.2B (range $4.7B–$51.2B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 1.53× the median modeled value of Growth/Late Biotechnology companies in 2019–2021 (5 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Last raise 5.7 yr ago; this sector typically re-raises about every 14 months.
Only one round on record and long silent — often defunct, acquired, or gone quiet.
Comparablesmixed
Capital scale ranks ahead of 100% of Biotechnology peers (4293 compared).
Modeled value ranks above 100% of those peers.
Closest niche peers: Sana Biotechnology, Inc., Neumora Therapeutics, Inc., Intarcia Therapeutics, Inc, Vaxxinity, Inc..
Peoplefiled
15 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.